We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent Gets Expanded FDA Approval for pharmDX Assay in U.S.
Read MoreHide Full Article
Agilent Technologies, Inc. (A - Free Report) continues to gain traction in the medical diagnosis market on the back of advanced techniques, and robust clinical and diagnostic product portfolio.
Notably, Agilent has received FDA approval on expanded use of the company’s PD-L1 IHC 22C3 pharmDx assay.
Post the approval, Agilent can now use the assay as an aid for the identification of patients with triple-negative breast cancer (“TNBC”) for treatment with KEYTRUDA by leveraging combined positive score.
Notably, KEYTRUDA is an anti-PD-1 therapy. The therapy boosts the ability of the immune system to detect and fight tumor cells. PD-L1 IHC 22C3 pharmDx is the sole companion diagnostic, approved by FDA, which can be used for the treatment of TNBC patients with KEYTRUDA along with chemotherapy.
Currently, the healthcare sector is witnessing a revolution. Companion diagnostics or personalized medicine is taking the center stage as it could provide improved patient care and better manage costs by administering the most appropriate treatment to individuals. It has been found that not all treatments are suitable for patients suffering from a specific disease as some require more specialized tests.
Agilent along with PD-L1 IHC 22C3’s strengthening detection capability of TNBC is likely to gain momentum in the global companion diagnostics market.
Per a report from MarketsandMarkets, the companion diagnostics market is expected to reach $6.8 billion by 2025 from $3.7 billion in 2020, at a CAGR of 12.9% from 2020 to 2025.
Notably, breast cancer is the most common type of cancer among women and the increasing occurrence of TNBC in such patients is boosting demand for companion diagnostics.
Moreover, high prevalence of such cases calls for these products that detect cancer during the early stages.
Bottom Line
Agilent’s expanding product portfolio and increased focus on segments with higher growth potential are key growth drivers. Growth in the pharmaceutical market on the back of solid momentum across both small and large molecule applications remains a positive.
Apart from the extended capability in TNBC cancer form, the product line is also helpful in the identification of non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, cervical cancer, urothelial carcinoma, and head and neck squamous cell carcinoma patients for treatment with KEYTRUDA.
PD-L1 IHC 22C3 also identifies patients with non-small cell lung cancer for KEYTRUDA treatment by using tumor proportion score.
We believe the latest FDA approval will further help the company to cash in on the fast-growing healthcare companion diagnostics segment.
Zacks Rank
Currently, Agilent carries a Zacks Ranks #3 (Hold). Some better-ranked stocks in the broader technology sector include Marchex (MCHX - Free Report) , Overstock.com and Maxim Integrated Products, Inc. , each carrying a Zacks Rank #2 (Buy).
Long-term earnings growth for Marchex, Overstock.com, and Maxim is currently projected at 15%, 20% and 10%, respectively.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Agilent Gets Expanded FDA Approval for pharmDX Assay in U.S.
Agilent Technologies, Inc. (A - Free Report) continues to gain traction in the medical diagnosis market on the back of advanced techniques, and robust clinical and diagnostic product portfolio.
Notably, Agilent has received FDA approval on expanded use of the company’s PD-L1 IHC 22C3 pharmDx assay.
Post the approval, Agilent can now use the assay as an aid for the identification of patients with triple-negative breast cancer (“TNBC”) for treatment with KEYTRUDA by leveraging combined positive score.
Notably, KEYTRUDA is an anti-PD-1 therapy. The therapy boosts the ability of the immune system to detect and fight tumor cells. PD-L1 IHC 22C3 pharmDx is the sole companion diagnostic, approved by FDA, which can be used for the treatment of TNBC patients with KEYTRUDA along with chemotherapy.
Agilent Technologies, Inc. Price and Consensus
Agilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. Quote
Growing Companion Diagnostics Market
Currently, the healthcare sector is witnessing a revolution. Companion diagnostics or personalized medicine is taking the center stage as it could provide improved patient care and better manage costs by administering the most appropriate treatment to individuals. It has been found that not all treatments are suitable for patients suffering from a specific disease as some require more specialized tests.
Agilent along with PD-L1 IHC 22C3’s strengthening detection capability of TNBC is likely to gain momentum in the global companion diagnostics market.
Per a report from MarketsandMarkets, the companion diagnostics market is expected to reach $6.8 billion by 2025 from $3.7 billion in 2020, at a CAGR of 12.9% from 2020 to 2025.
Notably, breast cancer is the most common type of cancer among women and the increasing occurrence of TNBC in such patients is boosting demand for companion diagnostics.
Moreover, high prevalence of such cases calls for these products that detect cancer during the early stages.
Bottom Line
Agilent’s expanding product portfolio and increased focus on segments with higher growth potential are key growth drivers. Growth in the pharmaceutical market on the back of solid momentum across both small and large molecule applications remains a positive.
Apart from the extended capability in TNBC cancer form, the product line is also helpful in the identification of non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, cervical cancer, urothelial carcinoma, and head and neck squamous cell carcinoma patients for treatment with KEYTRUDA.
PD-L1 IHC 22C3 also identifies patients with non-small cell lung cancer for KEYTRUDA treatment by using tumor proportion score.
We believe the latest FDA approval will further help the company to cash in on the fast-growing healthcare companion diagnostics segment.
Zacks Rank
Currently, Agilent carries a Zacks Ranks #3 (Hold). Some better-ranked stocks in the broader technology sector include Marchex (MCHX - Free Report) , Overstock.com and Maxim Integrated Products, Inc. , each carrying a Zacks Rank #2 (Buy).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Long-term earnings growth for Marchex, Overstock.com, and Maxim is currently projected at 15%, 20% and 10%, respectively.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>